{"id":18770,"date":"2020-04-08T10:20:45","date_gmt":"2020-04-08T08:20:45","guid":{"rendered":"https:\/\/www.satt.fr\/?p=18770"},"modified":"2020-04-08T10:48:30","modified_gmt":"2020-04-08T08:48:30","slug":"erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/","title":{"rendered":"Erganeo signs a license agreement with Evora Biosciences, a pioneer in\u00a0 next-generation cellular therapies"},"content":{"rendered":"

On Friday 13 March, Erganeo and start-up Evora Biosciences signed a world-exclusive license agreement for a new-generation digestive fistula cellular therapy treatment.<\/strong>
\nPicture from left to right: Naceur Tounekti, Vice-President of Erganeo and Hadrien Lanvin, CEO of Evora Biosciences<\/p>\n

A condition with serious consequences, and complex cases that are inadequately treated<\/strong>
\nAn estimated 1.2 million people across Europe and the United States suffer from digestive fistulas. A fistula is a physical anomaly in which two cavities inside the body interact abnormally. Digestive fistulas, more specifically, refer to interaction between the digestive tract and another organ and\/or the skin. \u00a0These frequently occur in people with auto-immune diseases such as Crohn\u2019s disease, or in patients that have undergone digestive system surgery, such as those carried out as a result of obesity or cancer. Each patient\u2019s initial state frequently impacts on a situation that is complex enough as it is.
\nOnce diagnosed, this condition requires fast treatment, particularly as secondary complications have serious consequences on patients\u2019 quality of life (pain, tiredness, malnutrition, multiple devices). In the most complex cases, patients\u2019 long-term quality of life can ultimately be affected. In addition, the surgical and treatment options open to medical practitioners carry high failure rates and significant associated risks.<\/p>\n

Evora Biosciences and the next generation of cellular therapies<\/strong>
\nThe cellular therapy treatment currently available is based on stem cell injections. Founded in March 2020, Evora Biosciences now offers a new approach. Using their technique, stem cells are no longer injected but are instead used to produce extracellular vesicles, also known as exosomes, which facilitate intercellular communication and regenerate damaged tissue in a similar way to the stem cells\u00a0that produce them. These extracellular vesicles are incorporated in an occlusive gel that is injected into the fistula.
\nUsing extracellular vesicles will make it possible to overcome part of the risk associated with the administration of stem cells. Evora Biosciences also intends to replicate the effects of traditional cellular therapy by reducing patient risk while offering a simplified logistical model that is compatible with wide-scale production.
\nThis technology was developed at the Mati\u00e8re et Syst\u00e8mes Complexes laboratory (UMR 7057) by a number of researchers from the Universit\u00e9 de Paris, APHP, CNRS, and Inserm laboratories: \u00a0Amanda Silva Brun, Gabriel Rahmi, Florence Gazeau, Claire Wilhelm, Christophe Cellier and Olivier Clement. Erganeo is responsible for managing the patent, which covers the use of an extracellular vesicle gel to treat digestive fistulas and was registered in 2017.<\/p>\n

\nSuat Topsu, CEO of Erganeo, is delighted with this new license agreement: \u201cErganeo is proud to be assisting with the emergence of this new generation of cellular therapy aimed at reducing complexity of use for medical personnel as well as patient risk\u201d.
\nHadrien Lanvin, CEO of Evora Biosciences, explains that \u201csigning this license marks a first step in shifting towards treatment that will be a game-changer for many patients\u2019 lives. For Evora Biosciences, this is also the first stage in the journey towards developing next-generation cellular therapies.\u201d<\/p>\n

Presse release<\/strong><\/a><\/p>\n

www.erganeo.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

On Friday 13 March, Erganeo and start-up Evora Biosciences signed a world-exclusive license agreement for a new-generation digestive fistula cellular therapy treatment. Picture from left to right: Naceur Tounekti, Vice-President of Erganeo and Hadrien Lanvin, CEO of Evora Biosciences A condition with serious consequences, and complex cases that are inadequately treated An estimated 1.2 million […]<\/p>\n","protected":false},"author":22,"featured_media":18967,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[568],"tags":[],"class_list":["post-18770","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-successstories-en"],"acf":[],"yoast_head":"\nErganeo signs a license agreement with Evora Biosciences, a pioneer in\u00a0 next-generation cellular therapies - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Estelle VIDAL\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/\"},\"author\":{\"name\":\"Estelle VIDAL\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/f31631111412086f92f3dd2a2e132823\"},\"headline\":\"Erganeo signs a license agreement with Evora Biosciences, a pioneer in\u00a0 next-generation cellular therapies\",\"datePublished\":\"2020-04-08T08:20:45+00:00\",\"dateModified\":\"2020-04-08T08:48:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/\"},\"wordCount\":512,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/04\/ERG.png\",\"articleSection\":[\"Success Stories\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/\",\"url\":\"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/\",\"name\":\"Erganeo signs a license agreement with Evora Biosciences, a pioneer in\u00a0 next-generation cellular therapies - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/04\/ERG.png\",\"datePublished\":\"2020-04-08T08:20:45+00:00\",\"dateModified\":\"2020-04-08T08:48:30+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/f31631111412086f92f3dd2a2e132823\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/04\/ERG.png\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/04\/ERG.png\",\"width\":1270,\"height\":708},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Erganeo signs a license agreement with Evora Biosciences, a pioneer in\u00a0 next-generation cellular therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d'Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/f31631111412086f92f3dd2a2e132823\",\"name\":\"Estelle VIDAL\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/estelle\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Erganeo signs a license agreement with Evora Biosciences, a pioneer in\u00a0 next-generation cellular therapies - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/","twitter_misc":{"Written by":"Estelle VIDAL","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/"},"author":{"name":"Estelle VIDAL","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/f31631111412086f92f3dd2a2e132823"},"headline":"Erganeo signs a license agreement with Evora Biosciences, a pioneer in\u00a0 next-generation cellular therapies","datePublished":"2020-04-08T08:20:45+00:00","dateModified":"2020-04-08T08:48:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/"},"wordCount":512,"image":{"@id":"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/04\/ERG.png","articleSection":["Success Stories"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/","url":"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/","name":"Erganeo signs a license agreement with Evora Biosciences, a pioneer in\u00a0 next-generation cellular therapies - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/04\/ERG.png","datePublished":"2020-04-08T08:20:45+00:00","dateModified":"2020-04-08T08:48:30+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/f31631111412086f92f3dd2a2e132823"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/04\/ERG.png","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/04\/ERG.png","width":1270,"height":708},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/erganeo-signs-a-license-agreement-with-evora-biosciences-a-pioneer-in-next-generation-cellular-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Erganeo signs a license agreement with Evora Biosciences, a pioneer in\u00a0 next-generation cellular therapies"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d'Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/f31631111412086f92f3dd2a2e132823","name":"Estelle VIDAL","url":"https:\/\/www.satt.fr\/en\/author\/estelle\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/18770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/22"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=18770"}],"version-history":[{"count":3,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/18770\/revisions"}],"predecessor-version":[{"id":18776,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/18770\/revisions\/18776"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/18967"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=18770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=18770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=18770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}